Showing results (61-70 of 71) with videos related to
Sort By:
Pageof 8
Signal Transduction and Targeted Therapy|December 9, 2024
Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trialYaoping Shi, Dan Cui, Lei Xia, et al.Nature Reviews. Cancer|September 2, 2024
Cancer drug-tolerant persister cells: from biological questions to clinical opportunitiesMariangela Russo, Mengnuo Chen, Elisa Mariella, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2019
BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast CancerLouise Walsh, Kathryn E Haley, Bruce Moran, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2026
PI3K inhibition in combination with tamoxifen in patients with metastatic HR+/HER2- breast cancer: clinical and circulating tumor DNA resultsRosie A B Voorthuis, Mafalda Oliveira, Annelot G J van Rossum, et al.Cell Reports. Medicine|November 17, 2022
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancerKatrin J Frank, Antonio Mulero-Sánchez, Alexandra Berninger, et al.Nature|March 28, 2014
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanomaChong Sun, Liqin Wang, Sidong Huang, et al.Oncoimmunology|December 8, 2018
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survivalMarcelo Sobral-Leite, Koen Van de Vijver, Magali Michaut, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2024
A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated MelanomaAlaa Embaby, Sanne C F A Huijberts, Liqin Wang, et al.Nature Medicine|October 13, 2015
The consensus molecular subtypes of colorectal cancerJustin Guinney, Rodrigo Dienstmann, Xin Wang, et al.Cancer Discovery|March 27, 2024
Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment StrategyMatheus Henrique Dias, Anoek Friskes, Siying Wang, et al.Pageof 8